A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 244,386 shares of ARQT stock, worth $3.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
244,386
Holding current value
$3.1 Million
% of portfolio
0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.32 - $11.0 $2.03 Million - $2.69 Million
244,386 New
244,386 $2.27 Million
Q4 2023

Feb 14, 2024

BUY
$1.84 - $4.82 $589,352 - $1.54 Million
320,300 New
320,300 $1.03 Million
Q1 2023

May 15, 2023

SELL
$10.23 - $17.14 $11.3 Million - $18.9 Million
-1,103,576 Closed
0 $0
Q4 2022

Feb 14, 2023

SELL
$13.96 - $20.4 $37.4 Million - $54.7 Million
-2,681,701 Reduced 70.85%
1,103,576 $16.3 Million
Q3 2022

Nov 14, 2022

BUY
$17.85 - $26.95 $32.1 Million - $48.5 Million
1,797,846 Added 90.46%
3,785,277 $72.3 Million
Q2 2022

Aug 15, 2022

BUY
$16.33 - $22.2 $4.73 Million - $6.43 Million
289,582 Added 17.06%
1,987,431 $42.4 Million
Q1 2022

May 16, 2022

SELL
$14.38 - $22.79 $13.6 Million - $21.6 Million
-946,328 Reduced 35.79%
1,697,849 $32.7 Million
Q4 2021

Feb 14, 2022

BUY
$14.98 - $25.5 $9.77 Million - $16.6 Million
652,070 Added 32.73%
2,644,177 $54.8 Million
Q3 2021

Nov 15, 2021

BUY
$19.28 - $27.1 $21.1 Million - $29.7 Million
1,095,707 Added 122.23%
1,992,107 $47.6 Million
Q2 2021

Aug 16, 2021

BUY
$24.42 - $34.75 $11.2 Million - $15.9 Million
457,100 Added 104.05%
896,400 $24.5 Million
Q1 2021

May 17, 2021

SELL
$24.47 - $36.98 $10.7 Million - $16.1 Million
-435,900 Reduced 49.81%
439,300 $12.7 Million
Q4 2020

Feb 16, 2021

BUY
$17.82 - $31.73 $14.8 Million - $26.4 Million
831,944 Added 1923.3%
875,200 $24.6 Million
Q3 2020

Nov 16, 2020

BUY
$23.44 - $32.28 $1.01 Million - $1.4 Million
43,256 New
43,256 $1.27 Million

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $763M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.